Acrux gets go-ahead for Phase III
Wednesday, 25 June, 2008
The US FDA has granted Acrux (ASX: ACR) approval to commence Phase III clinical trials of its Testostorone MD-Lotion.
The open-label trial will involve up to 150 hypogonadal men, who will take the recommended dosage for a period of four months.
Thanks to the approval, Acrux remains on target to launch the product in the fourth quarter of 2009, the company said.
Acrux said the product had several distinct advantages over current leading testosterone treatments.
It is a quick-drying solution that is applied to the armpits via a no-touch applicator, compared to the current treatments of a slow-drying gel which must be rubbed into the shoulders, upper torso or arms.
Low testosterone sufferers undergoing current treatments run the risk of transferring the drug to others due to treatment residue remaining on the hands.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
